501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haolin, Wei, Pengcheng, Zhang, Qianqian, Chen, Zhongzhou, Aviszus, Katja, Downing, Walter, Peterson, Shelley, Reynoso, Lyndon, Downey, Gregory P., Frankel, Stephen K., Kappler, John, Marrack, Philippa, Zhang, Gongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183533/
https://www.ncbi.nlm.nih.gov/pubmed/34074219
http://dx.doi.org/10.1080/19420862.2021.1919285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183533/
https://www.ncbi.nlm.nih.gov/pubmed/34074219
http://dx.doi.org/10.1080/19420862.2021.1919285

Ejemplares similares